Compare Becton Dickinson and Co (BDX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Regeneron Pharmaceuticals Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $42.39B), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $69.52B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| BDX | REGN | |
|---|---|---|
Market Cap | $42.39B | $69.52B |
Sector | Health | Health |
52-Week High | $185.39 | $812.27 |
52-Week Low | $135.49 | $542.52 |
Enterprise Value | $58.85B | $63.47B |
Dividend Yield | 2.73% | 0.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
